The treatment of inflammatory bowel disease has changed dramatically since the introduction of biologics and small molecule therapeutics. But does that mean older therapies no longer have any role? David...
Some patients with IBD require surgery to improve symptoms and quality of life. Joel Goldberg, MD, explained how to help patients prepare for surgery and achieve optimum recovery at the Advances in...
Because patients with IBD are at an increased risk for venous thromboembolisms, authors of a new study presented at the 2019 AIBD Meeting sought to determine the rate of deep vein thrombosis prophylaxis in...
Meenakshi Bewtra, MD, MPH, PhD, from the University of Pennsylvania, discussed medication failure as an important, but often forgotten, risk associated with 5-ASA in IBD, during a presentation at the 2019...
Ulcerative colitis (UC) is associated with a higher risk of colorectal cancer (CRC), but national data on admissions of CRC among patients with UC are scarce. Authors of a study presented at the 2019 AIBD...
Anti-tumor necrosis factor agents and/or thiopurines can prevent recurrence of Crohn disease in surgically treated patients, said Miguel Regueiro, MD, from the Cleveland Clinic, at the 2019 AIBD Meeting. ...
James Lewis, MD, explained how diet can influence the risk of developing Crohn disease and ulcerative colitis, as well as patient symptoms, during a presentation at the 2019 AIBD Meeting.
A retrospective observational cohort study presented at AIBD 2019 suggests that combination biologic therapy may be effective for certain patients with IBD.
In a new study presented at the 2019 AIBD Meeting, researchers assessed the prevalence of anastomotic ring inflammation (ARI) in patients with Crohn disease who undergo ileal resection and ileocolonic...
